Tassos Gianakakos
Vorstandsvorsitzender bei MYOKARDIA, INC.
Vermögen: 112 536 $ am 30.04.2024
Aktive Positionen von Tassos Gianakakos
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
MYOKARDIA, INC. | Vorstandsvorsitzender | 01.10.2013 | - |
Direktor/Vorstandsmitglied | 01.10.2013 | 17.11.2020 | |
Präsident | 01.10.2013 | 17.11.2020 | |
LIANBIO | Direktor/Vorstandsmitglied | 01.08.2020 | - |
Independent Dir/Board Member | 01.08.2020 | - | |
Prolaio, Inc.
Prolaio, Inc. BiotechnologyHealth Technology Prolaio, Inc. is a company founded in 2021 that engages in research and development of medical. The company is based in Scottsdale, AZ. | Direktor/Vorstandsmitglied | - | - |
Präsident | - | - |
Karriereverlauf von Tassos Gianakakos
Ehemalige bekannte Positionen von Tassos Gianakakos
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
MAP Pharmaceuticals LLC
MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology MAP Pharmaceuticals, Inc. develops therapies and inhalation delivery technologies. The company was founded by Thomas A. Armer on July 3, 2003 and is headquartered in Irvine, CA. | Corporate Officer/Principal | 01.09.2006 | 01.03.2013 |
MERCK & CO., INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.1997 | 01.01.1997 |
CODEXIS, INC. | Präsident | 01.01.2001 | - |
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Corporate Officer/Principal | - | - |
Ausbildung von Tassos Gianakakos
Massachusetts Institute of Technology | Undergraduate Degree |
Northwestern University | Graduate Degree |
Harvard Business School | Masters Business Admin |
Statistik
International
Vereinigte Staaten | 11 |
Operativ
President | 3 |
Director/Board Member | 3 |
Corporate Officer/Principal | 2 |
Sektoral
Health Technology | 6 |
Consumer Services | 3 |
Finance | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
MERCK & CO., INC. | Health Technology |
CODEXIS, INC. | Process Industries |
LIANBIO | Health Technology |
Private Unternehmen | 4 |
---|---|
MAP Pharmaceuticals LLC
MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology MAP Pharmaceuticals, Inc. develops therapies and inhalation delivery technologies. The company was founded by Thomas A. Armer on July 3, 2003 and is headquartered in Irvine, CA. | Health Technology |
MyoKardia, Inc.
MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. | Health Technology |
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Commercial Services |
Prolaio, Inc.
Prolaio, Inc. BiotechnologyHealth Technology Prolaio, Inc. is a company founded in 2021 that engages in research and development of medical. The company is based in Scottsdale, AZ. | Health Technology |
- Börse
- Insiders
- Tassos Gianakakos
- Erfahrung